Evaluation of DiaSorin Liaison® calprotectin fecal assay adapted for pleural effusion Authors: Cristina de Paz Poves, Clara Barneo-Caragol, Ana Isabel Cillero Sánchez, Lucía Jimenez Mendiguchia, Covadonga Quirós Caso, María Moreno Rodríguez, Francisco J. López González, Mᵃ Belén Prieto García Published: 2023 ABSTRACT AbstractObjectivesCalprotectin (CP) is a calcium and zinc binding protein that is widely measured on faecal samples but its determination in other biological fluids might be of interest. The aim of this work was to validate the measurement of CP in pleural fluid by chemiluminescence.MethodsLIAISON®XL, a fully automated chemiluminescence analyzer, was used for CP quantification on pleural fluid. A validation protocol was designed using both quality control materials provided by the manufacturer and pools of pleural fluid samples. Stability, imprecision, bias, linearity, detection capability and carry over effect were evaluated.ResultsCP was stable on pleural fluid at least one week, under refrigerated conditions, and four weeks at −80 °C. The observed intra- and inter-day imprecision was between 2.2 and 6.49 %, with a negative bias under 5.51 %. The linearity of the method was verified up to 2,000 ng/mL. The LoQ for the assay was 48.52 ng/mL. A statistically significant carry-over effect was observed after measuring CP concentrations above the upper limit of linearity, but given the observed magnitude, a clinically relevant impact should not be expected.ConclusionsDiaSorin Liaison® calprotectin assay allows reliable measurement of CP in pleural fluid. Introduction Calprotectin (CP) (S100A8/S100A9) is a calcium and zinc binding protein of 36 kDa, member of the S100 family of proteins [1]. It is mainly released from the neutrophils, with high levels described in inflammatory processes as a sign of the neutrophil chemotaxis [2]. In clinical practice, fecal CP measurement [3] is widely used for the diagnosis and monitoring of patients suffering from chronic inflammatory gastrointestinal disorders [4], but CP can be measured in other biological fluids [5], such as pleural effusions. Recent studies have pointed out its clinical utility to accurately predict malignancy, but all have used ELISA procedures [6], [7], [8] which, among other limitations, are not suitable for tests that require short response times. However, fully automated, fast and reliable methods are nowadays available. The aim of this work was to validate the measurement of CP in pleural fluid by chemiluminescence, hypothesizing that this method could provide better clinical performance than ELISA. Materials and methods Assay principle and instrument LIAISON®XL (DiaSorin, Italy), a fully automated chemiluminescence analyzer, was used for CP quantification on pleural fluid. This analyzer was designed for the quantification of fecal calprotectin so results are expressed in µg/g. Based on previous publication [9] a conversion factor of 2.5 was used to transform these units into ng/mL for the pleural fluid sample. The calibration curve was also transformed, being the measurement range of 12.50–2,000 ng/mL. Materials A validation protocol was designed using quality control materials provided by the manufacturer (Control 1 and 2) and pools of pleural fluid samples. Twenty pleural fluid samples obtained by thoracentesis were collected on sodium heparin tubes, immediately sent to the laboratory and centrifuged for 5 min at 415×g. Then, the supernatant was separated to be analyzed. Pools were made by homogeneous mixing of various pleural fluid samples until reaching the desired concentration. Stability Stability was evaluated following the Guidelines from Spanish Society of Laboratory Medicine (SEQCML) [10]. First, three sample pools with different CP concentrations were obtained from nine pleural fluid samples (three samples each pool): pool 1 (350 ng/mL), pool 2 (11,340 ng/mL), and pool 3 (145,525 ng/mL). All the pools were split into different aliquots. Three aliquots of each concentration were stored at 4 °C and five at −80°. Refrigerated aliquots were analyzed every 2–3 days over a week, whereas frozen aliquots were analyzed once a week over 5 weeks. Stability was expressed as the difference between concentration at each storage condition and its correspondent basal level (percentage deviation, PD %). Maximum permissible instability (MPI) was set at ±10 %. Imprecision and bias Imprecision was evaluated according to Clinical and Laboratory Standards Institute (CLSI) guideline EP15 [11]. Two pools obtained from six pleural fluid samples (three samples each pool) with concentrations similar to quality control materials were tested, CP target value being 607.5 ng/mL and 121.12 ng/mL for Controls 1 and 2, respectively. Five replicates were run on a single day (intra-day imprecision) for five consecutive days (inter-day imprecision). The referred two levels of quality controls were also tested in three replicates for five consecutive days. Results were expressed as % coefficient of variation (CV). Bias was estimated based on internal quality control materials. Linearity The guideline CLSI EP06 [12] was followed to verify the linearity. A high concentration pool obtained from three pleural fluid samples (−10 % of upper quantification limit) was diluted with a low concentration pool obtained from another three pleural fluid samples (+10 % of lower quantification limit) in different proportions (1, 0.75, 0.5, 0.25 and 0 % of high pool), covering the dynamic range of the assay. Duplicates of each level were run on a single day. Linearity was assessed by plotting the % deviation between measured vs. predicted values. The allowable deviation from linearity (ADL) was set at ±